Anixa Biosciences, Inc. (ANIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANIX POWR Grades
- ANIX scores best on the Sentiment dimension, with a Sentiment rank ahead of 42.85% of US stocks.
- The strongest trend for ANIX is in Value, which has been heading down over the past 160 days.
- ANIX ranks lowest in Value; there it ranks in the 4th percentile.
ANIX Stock Summary
- With a price/sales ratio of 156.98, Anixa Biosciences Inc has a higher such ratio than 98.36% of stocks in our set.
- ANIX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.59% of US stocks.
- With a year-over-year growth in debt of 370.09%, Anixa Biosciences Inc's debt growth rate surpasses 96.64% of about US stocks.
- Stocks that are quantitatively similar to ANIX, based on their financial statements, market capitalization, and price volatility, are WIMI, LBPS, XM, PLTR, and INVZ.
- ANIX's SEC filings can be seen here. And to visit Anixa Biosciences Inc's official web site, go to www.anixa.com.
ANIX Valuation Summary
- In comparison to the median Healthcare stock, ANIX's price/sales ratio is 8518.42% higher, now standing at 327.5.
- Over the past 243 months, ANIX's EV/EBIT ratio has gone down 8.
- Over the past 243 months, ANIX's EV/EBIT ratio has gone down 8.
Below are key valuation metrics over time for ANIX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ANIX | 2021-08-31 | 327.5 | 4.5 | -17.9 | -14.9 |
| ANIX | 2021-08-30 | 320.5 | 4.4 | -17.5 | -14.5 |
| ANIX | 2021-08-27 | 307.0 | 4.2 | -16.7 | -13.8 |
| ANIX | 2021-08-26 | 286.7 | 3.9 | -15.6 | -12.7 |
| ANIX | 2021-08-25 | 290.2 | 4.0 | -15.8 | -12.9 |
| ANIX | 2021-08-24 | 266.2 | 3.6 | -14.5 | -11.6 |
ANIX Growth Metrics
- Its 5 year revenue growth rate is now at -100%.
- Its 5 year cash and equivalents growth rate is now at 10.56%.
- The 4 year revenue growth rate now stands at -100%.
The table below shows ANIX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-09-30 | 0.5125 | -4.936881 | -12.9544 |
| 2021-06-30 | 0.5125 | -5.306789 | -11.16517 |
| 2021-03-31 | 0.5125 | -5.116963 | -9.392861 |
| 2020-12-31 | 0.5125 | -5.431713 | -9.634103 |
| 2020-09-30 | 0 | -6.175671 | -10.01835 |
| 2020-06-30 | 0 | -6.09863 | -9.881813 |
ANIX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ANIX has a Quality Grade of F, ranking ahead of 4.41% of graded US stocks.
- ANIX's asset turnover comes in at 0.021 -- ranking 366th of 682 Pharmaceutical Products stocks.
- ALIM, BDSI, and ACOR are the stocks whose asset turnover ratios are most correlated with ANIX.
The table below shows ANIX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-07-31 | 0.021 | 0.249 | -2.121 |
| 2021-04-30 | 0.029 | 0.249 | -2.555 |
| 2021-01-31 | 0.052 | 0.249 | -5.229 |
| 2020-10-31 | 0.000 | NA | -4.690 |
| 2020-07-31 | 0.000 | NA | -4.964 |
| 2020-04-30 | 0.000 | NA | -5.669 |
ANIX Price Target
For more insight on analysts targets of ANIX, see our ANIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.75 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ANIX Stock Price Chart Interactive Chart >
ANIX Price/Volume Stats
| Current price | $3.59 | 52-week high | $5.87 |
| Prev. close | $3.53 | 52-week low | $2.30 |
| Day low | $3.43 | Volume | 7,344 |
| Day high | $3.60 | Avg. volume | 78,356 |
| 50-day MA | $2.95 | Dividend yield | N/A |
| 200-day MA | $3.64 | Market Cap | 108.17M |
Anixa Biosciences, Inc. (ANIX) Company Bio
Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.
Latest ANIX News From Around the Web
Below are the latest news stories about Anixa Biosciences Inc that investors may wish to consider to help them evaluate ANIX as an investment opportunity.
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer VaccineAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Japanese Patent Office has issued a Decision to Grant of a patent to Cleveland Clinic titled, "Ovarian Cancer Vaccines." The technology was invented by Drs. Vincent K. Tuohy, Suparna Mazumder and Justin M. Johnson at Cleveland Clinic. Anixa is the worldwide licensee for the vaccine technology. Patents for the technology were issued in |
Anixa says new protease inhibitor outperformed main agent in Pfizer’s COVID-19 pillAnixa Biosciences (ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent… |
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease InhibitorAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer's PAXLOVID™, which was recently authorized to treat COVID-19. PAXLOVID also includes ritonavir, wh |
Anixa Biosciences to Participate in Upcoming January Investor Conferences: LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect ConferenceAnixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held January 10-13, 2022. |
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
ANIX Price Returns
| 1-mo | 33.96% |
| 3-mo | 31.74% |
| 6-mo | -9.80% |
| 1-year | -10.92% |
| 3-year | -10.92% |
| 5-year | 277.89% |
| YTD | 20.88% |
| 2021 | -3.26% |
| 2020 | -6.40% |
| 2019 | -16.75% |
| 2018 | 66.95% |
| 2017 | -56.30% |
Continue Researching ANIX
Here are a few links from around the web to help you further your research on Anixa Biosciences Inc's stock as an investment opportunity:Anixa Biosciences Inc (ANIX) Stock Price | Nasdaq
Anixa Biosciences Inc (ANIX) Stock Quote, History and News - Yahoo Finance
Anixa Biosciences Inc (ANIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...